KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Invested Capital (2016 - 2026)

Abbott Laboratories' Invested Capital history spans 18 years, with the latest figure at $86.1 billion for Q1 2026.

  • On a quarterly basis, Invested Capital rose 41.88% to $86.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $86.1 billion, a 41.88% increase, with the full-year FY2025 number at $65.5 billion, up 357.22% from a year prior.
  • Invested Capital hit $86.1 billion in Q1 2026 for Abbott Laboratories, up from $65.5 billion in the prior quarter.
  • Over the last five years, Invested Capital for ABT hit a ceiling of $86.1 billion in Q1 2026 and a floor of -$14.1 billion in Q3 2022.
  • Historically, Invested Capital has averaged $28.6 billion across 5 years, with a median of $15.0 billion in 2024.
  • Biggest five-year swings in Invested Capital: plummeted 1980.59% in 2022 and later surged 1454.56% in 2023.
  • Tracing ABT's Invested Capital over 5 years: stood at $41.5 billion in 2022, then tumbled by 64.51% to $14.7 billion in 2023, then dropped by 2.62% to $14.3 billion in 2024, then skyrocketed by 357.22% to $65.5 billion in 2025, then skyrocketed by 31.38% to $86.1 billion in 2026.
  • Business Quant data shows Invested Capital for ABT at $86.1 billion in Q1 2026, $65.5 billion in Q4 2025, and $64.1 billion in Q3 2025.